CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
时而可见，时而不见：使非恶性细胞免受 CAR-T 细胞疗法攻击的新策略
英文原题：Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies.
查看英文原题
Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管新型免疫疗法已革新肿瘤学领域，但其仍受限于无法区分癌细胞与健康造血干细胞和祖细胞（HSPC）。Casirati等人¹和Wellhausen等人²对AML及HSPC中共同表达的抗原进行表位编辑，开辟了多种新的免疫治疗靶点。
展开英文摘要原文
While new immunotherapies have revolutionized the field of oncology, they have been limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by Casirati et al. 1 and Wellhausen et al. 2 in epitope editing antigens commonly expressed on AML and HSPCs has unlocked several new targets for immunotherapies.
论文信息
- 作者
- Petty NE、Thomas J、Radtke S、Kiem HP
- 第一作者单位
- Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA.United States
- 通讯作者单位
- Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: hkiem@fredhutch.org.United States
- 文献类型
- 美国 NIH 资助研究
- 期刊
- Med (New York, N.Y.)2023 Nov 10
- 原文标识
- PubMed 37951207 · DOI 10.1016/j.medj.2023.10.004
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →